Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer

doi:10.1016/J.IJROBP.2005.0

Title: Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer

Full Record
Similar

Abstract

Purpose: The primary objective of this study was to evaluate the tolerance and toxicity of radiation therapy (RT) and capecitabine in patients with advanced, unresectable pancreatic carcinoma. To control micrometastatic disease, combination chemotherapy (gemcitabine and cisplatin) before and after combined modality therapy (CMT) was planned. Methods and Materials: Patients with unresectable or metastatic pancreatic cancer were eligible. Gemcitabine 1000 mg/m{sup 2} and cisplatin 35 mg/m{sup 2} were administered on Days 1 and 8 of a 21-day cycle for two cycles. RT was then given to a dose of 50.4 Gy in 1.8 Gy fractions. Patients were treated with capecitabine 1330 mg/m{sup 2} daily during RT. After CMT, two additional cycles of gemcitabine and cisplatin completed the treatment. Results: Twenty-three patients were treated. Eighteen patients completed CMT. One patient was removed from study during CMT for toxicity issues. Treatment delays and dose reductions were common during the final two cycles of gemcitabine and cisplatin as a result of myelosuppression. Median survival was 10.1 months (95% confidence interval [CI] = 7.6, 13.7) for all 23 patients and 12.8 months (95% CI = 8.2, 18.9) for 18 patients without metastasis. Conclusion: Combined modality therapy with RT and capecitabine was well tolerated. Chemotherapy aftermore »« less

Authors:

Schneider, Bryan J. ^[1]; Ben-Josef, Edgar ^[2]; McGinn, Cornelius J. ^[2]; Chang, Alfred E. ^[3]; Colletti, Lisa M. ^[3]; Normolle, Daniel P. ^[2]; Comprehensive Cancer Center Biostatistics Unit, University of Michigan Medical Center, Ann Arbor, MI ^[4]; Hejna, Gwen F. P.A. ^[1]; Lawrence, Theodore S. ^[2]; Zalupski, Mark M. ^[5]

Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI (United States)
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI (United States)
Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI (United States)
(United States)
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI (United States). E-mail: Zalupski@umich.edu

Publication Date:: Thu Dec 01 00:00:00 EST 2005

OSTI Identifier:: 20788222

Resource Type:: Journal Article

Resource Relation:: Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 63; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2005.04.030; PII: S0360-3016(05)00758-3; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; CHEMOTHERAPY; METASTASES; PANCREAS; PATIENTS; RADIOTHERAPY; TOXICITY; URACILS

Citation Formats


                    Schneider, Bryan J., Ben-Josef, Edgar, McGinn, Cornelius J., Chang, Alfred E., Colletti, Lisa M., Normolle, Daniel P., Comprehensive Cancer Center Biostatistics Unit, University of Michigan Medical Center, Ann Arbor, MI, Hejna, Gwen F. P.A., Lawrence, Theodore S., and Zalupski, Mark M.. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.  United States: N. p., 2005. 
        Web.  doi:10.1016/J.IJROBP.2005.0.

Copy to clipboard


                    Schneider, Bryan J., Ben-Josef, Edgar, McGinn, Cornelius J., Chang, Alfred E., Colletti, Lisa M., Normolle, Daniel P., Comprehensive Cancer Center Biostatistics Unit, University of Michigan Medical Center, Ann Arbor, MI, Hejna, Gwen F. P.A., Lawrence, Theodore S., & Zalupski, Mark M.. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.  United States.  doi:10.1016/J.IJROBP.2005.0.

Copy to clipboard


                    Schneider, Bryan J., Ben-Josef, Edgar, McGinn, Cornelius J., Chang, Alfred E., Colletti, Lisa M., Normolle, Daniel P., Comprehensive Cancer Center Biostatistics Unit, University of Michigan Medical Center, Ann Arbor, MI, Hejna, Gwen F. P.A., Lawrence, Theodore S., and Zalupski, Mark M.. Thu .  
        "Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer".  United States.  
        doi:10.1016/J.IJROBP.2005.0.

Copy to clipboard


                    
@article{osti_20788222,

  title        = {Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer},

  author       = {Schneider, Bryan J. and Ben-Josef, Edgar and McGinn, Cornelius J. and Chang, Alfred E. and Colletti, Lisa M. and Normolle, Daniel P. and Comprehensive Cancer Center Biostatistics Unit, University of Michigan Medical Center, Ann Arbor, MI and Hejna, Gwen F. P.A. and Lawrence, Theodore S. and Zalupski, Mark M.},

  abstractNote = {Purpose: The primary objective of this study was to evaluate the tolerance and toxicity of radiation therapy (RT) and capecitabine in patients with advanced, unresectable pancreatic carcinoma. To control micrometastatic disease, combination chemotherapy (gemcitabine and cisplatin) before and after combined modality therapy (CMT) was planned. Methods and Materials: Patients with unresectable or metastatic pancreatic cancer were eligible. Gemcitabine 1000 mg/m{sup 2} and cisplatin 35 mg/m{sup 2} were administered on Days 1 and 8 of a 21-day cycle for two cycles. RT was then given to a dose of 50.4 Gy in 1.8 Gy fractions. Patients were treated with capecitabine 1330 mg/m{sup 2} daily during RT. After CMT, two additional cycles of gemcitabine and cisplatin completed the treatment. Results: Twenty-three patients were treated. Eighteen patients completed CMT. One patient was removed from study during CMT for toxicity issues. Treatment delays and dose reductions were common during the final two cycles of gemcitabine and cisplatin as a result of myelosuppression. Median survival was 10.1 months (95% confidence interval [CI] = 7.6, 13.7) for all 23 patients and 12.8 months (95% CI = 8.2, 18.9) for 18 patients without metastasis. Conclusion: Combined modality therapy with RT and capecitabine was well tolerated. Chemotherapy after CMT was difficult to complete owing to cumulative myelosuppression. Survival, response, and toxicity were comparable to infusional 5-fluorouracil and RT.},

  doi          = {10.1016/J.IJROBP.2005.0},

  journal      = {International Journal of Radiation Oncology, Biology and Physics},

  number       = 5,

  volume       = 63,

  place        = {United States},

  year         = {Thu Dec 01 00:00:00 EST 2005},

  month        = {Thu Dec 01 00:00:00 EST 2005}

}

Copy to clipboard

Journal Article:

DOI: 10.1016/J.IJROBP.2005.0

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer

Desai, Sameer ; Ben-Josef, Edgar ; Griffith, Kent A. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To report outcomes for patients with resected pancreas cancer treated with an adjuvant regimen consisting of gemcitabine-based combination chemotherapy followed by capecitabine and radiation. Patients and Methods: We performed a retrospective review of a series of patients treated at a single institution with a common postoperative adjuvant program. Between January 2002 and August 2006, 43 resected pancreas cancer patients were offered treatment consisting of 4, 21-day cycles of gemcitabine 1 g/m{sup 2} intravenously over 30 min on Days 1 and 8, with either cisplatin 35 mg/m{sup 2} intravenously on Days 1 and 8 or capecitabine 1500 mg/m{sup 2} orallymore »« less
DOI: 10.1016/j.ijrobp.2009.01.023
NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer

Hong, Theodore S., E-mail: tshong1@mgh.harvard.edu ; Moughan, Jennifer ; Garofalo, Michael C. ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate the rate of gastrointestinal (GI) toxicity of neoadjuvant chemoradiation with capecitabine, oxaliplatin, and intensity modulated radiation therapy (IMRT) in cT3-4 rectal cancer. Methods and Materials: Patients with localized, nonmetastatic T3 or T4 rectal cancer <12 cm from the anal verge were enrolled in a prospective, multi-institutional, single-arm study of preoperative chemoradiation. Patients received 45 Gy with IMRT in 25 fractions, followed by a 3-dimensional conformal boost of 5.4 Gy in 3 fractions with concurrent capecitabine/oxaliplatin (CAPOX). Surgery was performed 4 to 8 weeks after the completion of therapy. Patients were recommended to receive FOLFOX chemotherapy after surgery. The primary endpoint ofmore »« less
DOI: 10.1016/J.IJROBP.2015.05.005
Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer

Esnaola, Nestor F. ; Chaudhary, Uzair B. ; O'Brien, Paul ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Methods and Materials: Patients received gemcitabine and oxaliplatin chemotherapy repeated every 14 days for 6 cycles, combined with weekly cetuximab. Patients were then restaged; “downstaged” patients with resectable disease underwent attempted resection. Remaining patients were treated with chemoradiation consisting of intensity modulated radiation therapy (54 Gy) and concurrent capecitabine; patients with borderline resectable disease or better at restaging underwent attempted resection. Results:more »« less
DOI: 10.1016/J.IJROBP.2013.12.030
Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer

Wong, Stuart J. ; Moughan, Jennifer ; Meropol, Neal J., E-mail: Neal.Meropol@case.edu ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To report secondary efficacy endpoints of Radiation Therapy Oncology Group protocol 0247, primary endpoint analysis of which demonstrated that preoperative radiation therapy (RT) with capecitabine plus oxaliplatin achieved a pathologic complete remission prespecified threshold (21%) to merit further study, whereas RT with capecitabine plus irinotecan did not (10%). Methods and Materials: A randomized, phase 2 trial evaluated preoperative RT (50.4 Gy in 1.8-Gy fractions) with 2 concurrent chemotherapy regimens: (1) capecitabine (1200 mg/m{sup 2}/d Monday-Friday) plus irinotecan (50 mg/m{sup 2}/wk × 4); and (2) capecitabine (1650 mg/m{sup 2}/d Monday-Friday) plus oxaliplatin (50 mg/m{sup 2}/wk × 5) for clinical T3 or T4 rectal cancer. Surgery was performed 4 tomore »« less
DOI: 10.1016/J.IJROBP.2014.09.031
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation

Krishnan, Sunil, E-mail: skrishnan@mdanderson.org ; Chadha, Awalpreet S. ; Suh, Yelin ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with curative intent. Methods and Materials: A total of 200 patients with LAPC were treated with induction chemotherapy followed by chemoradiation between 2006 and 2014. Of these, 47 (24%) having tumors >1 cm from the luminal organs were selected for dose-escalated IMRT (biologically effective dose [BED] >70 Gy) using a simultaneous integrated boost technique, inspiration breath hold, and computed tomographic image guidance. Fractionation was optimized for coverage of gross tumor and luminal organ sparing. A 2- to 5-mm margin around the gross tumor volume wasmore »« less
DOI: 10.1016/J.IJROBP.2015.12.003